Recurrent Breast Cancer Recruiting Phase 1 Trials for Trastuzumab emtansine (DB05773)

Also known as: Breast Cancer Recurrent / Breast cancer NOS recurrent / Carcinoma breast recurrent / Breast carcinoma recurrent / Breast carcinoma NOS recurrent

IndicationStatusPhase
DBCOND0028640 (Recurrent Breast Cancer)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02390427Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast CancerTreatment